First National Bank of Omaha Sells 5,322 Shares of Revvity Inc. $RVTY

First National Bank of Omaha cut its stake in shares of Revvity Inc. (NYSE:RVTY) by 7.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,062 shares of the company’s stock after selling 5,322 shares during the period. First National Bank of Omaha owned 0.06% of Revvity worth $6,585,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CYBER HORNET ETFs LLC bought a new stake in shares of Revvity during the second quarter valued at about $32,000. Cromwell Holdings LLC increased its position in shares of Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after buying an additional 198 shares during the period. MUFG Securities EMEA plc bought a new stake in shares of Revvity during the second quarter valued at about $34,000. Headlands Technologies LLC bought a new stake in shares of Revvity during the second quarter valued at about $49,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Revvity during the fourth quarter valued at about $51,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Stock Down 1.8%

RVTY stock opened at $99.66 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The company’s 50 day moving average is $94.91 and its 200 day moving average is $97.75. The stock has a market cap of $11.12 billion, a price-to-earnings ratio of 47.68, a price-to-earnings-growth ratio of 2.22 and a beta of 1.11. Revvity Inc. has a 1-year low of $81.22 and a 1-year high of $118.30.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The company had revenue of $711.12 million for the quarter, compared to analysts’ expectations of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. Revvity’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Sell-side analysts predict that Revvity Inc. will post 5.25 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Shareholders of record on Friday, July 17th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Friday, July 17th. Revvity’s dividend payout ratio (DPR) is presently 13.40%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on RVTY shares. Barclays upped their price target on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Wolfe Research started coverage on shares of Revvity in a research report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. The Goldman Sachs Group decreased their price objective on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 14th. Robert W. Baird set a $117.00 price objective on shares of Revvity in a research report on Wednesday, May 6th. Finally, Weiss Ratings cut shares of Revvity from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 13th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Revvity has an average rating of “Hold” and an average target price of $107.73.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.